Bezafibrate

Chemical formula: C₁₉H₂₀ClNO₄  Molecular mass: 361.819 g/mol  PubChem compound: 39042

Therapeutic indications

Bezafibrate is indicated for:

Severe hypertriglyceridaemia, mixed hyperlipidaemia

Population group: only adults (18 years old or older)

Bezafibrate is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following:

  • Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.
  • Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Bezafibrate is contraindicated in the following cases:

Severe renal failure (serum creatinine >530 μmol/l; creatinine clearance <15ml/min), dialysis, nephrotic syndrome

at least one of
Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)
Renal dialysis
Nephrotic syndrome

Pregnancy

Pregnancy

Lactation

Lactation

HMG CoA reductase inhibitors

HMG CoA reductase inhibitors

Gall bladder disease

Gallbladder disorder

Significant hepatic disease

at least one of
Hepatopathy
Hepatic insufficiency

Renal impairment

Renal failure

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: BEZAFIBRATE Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈